Trial · NCT01107639
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
NCT01107639, Phase 3, Completed, Swiss Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery. Trials, record NCT01107639. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01107639
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
- NCT number
- NCT01107639
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 297 participants, actual
- Lead sponsor
- Swiss Cancer Institute
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
- Interventions
- cetuximab, cisplatin, docetaxel, adjuvant therapy, neoadjuvant therapy
- First posted
- 2010-04-21
- Last updated
- 2020-10-20
- Other registries' IDs
- eudract:2009-016584-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | time from randomization to a defined event. | time from randomization to one of the following events, whichever comes first: * Tumor progression at any time (progression of primary tumor or local lymph nodes, appearance of new lesions) * Recurrence at local, regional or distant site after surgery * Death from any cause |
| Secondary | Progression-free survival after surgery | from date of surgery to an event as defined in PFS. | |
| Secondary | Adverse events according to CTCAE version 4.0 and major postoperative complications | during treatment and follow-up period. | |
| Secondary | Pathological remission | Assessed according to the tumor regression model of Mandard | |
| Secondary | Overall survival | time from trial randomization to the date of death from any cause | |
| Secondary | Time to locoregional failure after R0 resection | from date of surgery to date of first documented loco-regional failure | |
| Secondary | Time to systemic failure after R0 resection | from date of surgery to date of first documented systemic failure | |
| Secondary | In-hospital mortality | occurring after surgery but while the patient remains in hospital | |
| Secondary | Time to progression (TTP) | Time to progression is defined as time from randomization to one of the following events, whichever comes first: - Tumor progression at any time. - Recurrence at local, regional or distant site after surgery. - Death due to tumor |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01107639
GET https://conductscience.org/api/trials/v1/NCT01107639/registered